• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Peru Pharmaceuticals and Healthcare Report Q1 2013 - Product Image

Peru Pharmaceuticals and Healthcare Report Q1 2013

  • Published: January 2013
  • Region: Peru
  • 111 pages
  • Business Monitor International

FEATURED COMPANIES

  • AstraZeneca
  • Domestic Companies
  • GlaxoSmithKline
  • Merck & Co
  • Novartis
  • Sanofi
  • MORE

BMI View:

We have recently revised downwards our 2012 pharmaceutical sales growth for Peru, due to the recent price cuts in the prescription drug sector, which accounts for over 74% of total pharmaceutical sales. Still, our projected compound annual growth rate (CAGR) between 2011 and 2016 remains largely unchanged as BMI believes Peru still offers considerable longer-term benefits to local and foreign pharmaceutical companies because of the country's ageing population, increasing disease burden and the expected change in drug consumption patterns.

Headline Expenditure Projections

- Pharmaceuticals: PEN3.90bn (US$1.42bn) in 2011 to PEN4.11bn (US$1.57bn) in 2012; +5.3%
in local currency terms and +10.4% in US dollar terms. Forecast revised downwards from Q412 due to price cuts in the prescription drug sector.

- Healthcare: PEN19.52bn (US$7.09bn) in 2011 to PEN20.73bn (US$7.90bn) in 2012; +6.2% in local currency terms and +11.4% in US dollar terms. US dollar forecast unchanged from Q412.

- Medical devices: PEN897mn (US$326mn) in 2011 to PEN954mn (US$363mn) in 2012; +6.3%
in local currency terms and +11.6% in US dollar terms. Forecast slightly READ MORE >

Executive Summary 7

SWOT Analysis 9

Peru Pharmaceuticals And Healthcare Industry SWOT 9

Peru Political SWOT 10

Peru Economic SWOT 11

Peru Business Environment SWOT 11

Pharmaceutical Risk/Reward Ratings 12
Table: Americas Pharmaceutical Risk/Reward Ratings, Q113 12

Rewards 13

Risks 14

Peru - Market Summary 15

Regulatory Regime 16

Recent Regulatory Developments 17

Pharmaceutical Advertising 18

OTC Medicines 19

Phytotherapeutics 19

Regional Harmonisation 20

Intellectual Property Regime 20

IP Shortcomings 21

Counterfeit Pharmaceuticals 23

Trade Agreements 24

Pricing Regime 25
Table: Peruvian Watchdog of Pharmaceutical Products (Observatorio Peruano de Productos Farmacéuticos, OPPF) 26

Reimbursement Regime 26

Government Tenders 27
Table: Public Procurement of Pharmaceuticals by Provider, 2007-2009 (Million Soles) 28

Pricing And Reimbursement Developments 29

Industry Developments 32

Epidemiology 32
Table: Selected Causes of Death by Sex, 2010 32

Non-Communicable Diseases 35

Communicable Diseases 36

Healthcare Sector 38
Table: MINSA's Decentralised Institutions & Institutes, 2011 38

Healthcare Sector Developments 39

Healthcare Finances 41

Healthcare Provision 42
Table: Infrastructure, 2004-2009 42
Table: Key Goals of Parsalud II In Nine Regions 43

Health Insurance 43

Research and Development (R&D) 44

Clinical Trials 45

Medical Devices 46

Industry Forecast Scenario 48

Pharmaceutical Market Forecast 48
Table: Pharmaceutical Sales Indicators 2008-2016 50

Healthcare Market Forecast 51
Table: Healthcare Expenditure Indicators 2008-2016 52
Table: Healthcare Governmental Indicators 2008-2016 52
Table: Healthcare Private Indicators 2008-2016 53

Key Growth Factors - Macroeconomic 54
Table: Puru Macro Indicators 58

Prescription Drug Market Forecast 59
Table: Prescription Drug Sales Indicators 2008-2016 60

Patented Drug Market Forecast 61
Table: Patented Drug Market Indicators 2008-2016 62

Generic Drug Market Forecast 63
Table: Generic Drug Sales Indicators 2008-2016 66

OTC Medicine Market Forecast 67
Table: OTC Medicine Sales Indicators 2008-2016 68

Pharmaceutical Trade Forecast 69
Table: Exports and Imports Indicators 2008-2016 71

Medical Device Market Forecast 72
Table: Medical Devices Sales Indicators 2008-2016 73

Other Healthcare Data 74

Key Risks To BMI's Forecast Scenario 75

Competitive Landscape 76

Pharmaceutical Sector 76
Table: Peruvian Pharmaceutical Companies That Acquired GMP Accreditation In 2006 76

Table Members of ADIFAN, 2011 77
Table: Members of ALAFARPE, 2011 78
Table: Members of COMSALUD, 2011 78

Foreign Industry 80

Domestic Industry 82
Table: Domestic Production, 1992-2009 82

Pharmaceutical Distribution 83

Pharmaceutical Retail 84

Company Profiles 88

Domestic Companies 88

Farmaindustria 88

Unimed 90

Hersil 91

Multinational Companies 93

Sanofi 93

Merck & Co 94

GlaxoSmithKline 95

Novartis 96

Pfizer 97

AstraZeneca 98

Teva (Corporación Medco) 99

Demographic Outlook 101
Table: Peru's Population By Age Group, 1990-2020 ('000) 02
Table: Peru's Population By Age Group, 1990-2020 (% of total) 03
Table: Peru's Key Population Ratios, 1990-2020 04
Table: Peru's Rural And Urban Population, 1990-2020 04

Glossary 105

BMI Methodology 107

How We Generate Our Pharmaceutical Industry Forecasts 07

Pharmaceuticals Business Environment Ratings 08

Risk/Reward Ratings Methodology 08

Ratings Overview 08
Table: Pharmaceutical Business Environment Indicators 09

Weighting 10
Table: Weighting Of Components 10

Sources 10

Company Profiles
Domestic Companies
Farmaindustria
Unimed
Hersil
Multinational Companies
Sanofi
Merck & Co
GlaxoSmithKline
Novartis
Pfizer
AstraZeneca
Teva (Corporación Medco)

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos